Irazu Oncology

Irazu Oncology is an early-stage biotech developing novel, off-the-shelf cancer immunotherapies based on engineered bacterial outer membrane vesicles (OMVs). The company's platform, derived from over 15 years of academic research, is designed for scalable manufacturing to lower costs and improve accessibility compared to personalized cell therapies. Led by a seasoned team with extensive drug development experience, Irazu's lead candidate, IRZ-01, targets multiple solid tumors and represents a potentially disruptive approach in the immuno-oncology space.

Proprietary engineered bacterial Outer Membrane Vesicle (OMV) platform for off-the-shelf cancer immunotherapy. Designed for scalable manufacturing, modular antigen presentation, and activation of both innate and adaptive immune responses.

Irazu competes in the crowded immuno-oncology space against personalized CAR-T therapies, bispecific antibodies, and other off-the-shelf modalities like allogeneic cell therapies. Its key differentiator is the novel OMV delivery mechanism, promising lower cost and faster availability. Success hinges on demonstrating clinical advantages over these established and emerging approaches.